Dishman Carbogen Amcis Ltd has announced the approval for issuance of non-convertible debentures (NCDs) worth up to ₹50 crores, marking a significant capital raising initiative by the pharmaceutical company. The debentures are structured with attractive terms designed to appeal to income-seeking investors.

Debenture Structure and Terms

The approved NCDs will carry a coupon rate of 10.00% per annum, with interest payments scheduled on a quarterly basis. This payment frequency ensures regular income flow for investors throughout the tenure of the debentures.

Security Features

The debentures will be secured through multiple layers of protection to safeguard investor interests. The company has structured the NCDs with property-backed security, providing tangible asset coverage for the debt instruments. Additionally, corporate guarantees will further strengthen the security framework, offering investors enhanced protection against default risk.

Strategic Implications

This debt fundraising initiative reflects Dishman Carbogen Amcis Ltd's strategy to optimize its capital structure through debt financing. The 10.00% coupon rate positions the debentures competitively in the current market environment, while the quarterly payment structure caters to investors seeking regular income streams. The secured nature of these debentures, backed by properties and corporate guarantees, demonstrates the company's commitment to providing robust investor protection.

The approval of this NCD issuance provides Dishman Carbogen Amcis with access to up to ₹50.00 crores in funding, which can support various business operations and growth initiatives while maintaining the company's equity structure.

Dishman Carbogen Amcis Limited , a prominent player in the pharmaceutical industry, has officially approved the issuance of non-convertible debentures (NCDs) worth up to ₹50 crore. The Board of Directors made this decision during their meeting held on December 27, 2025, which commenced at 12:00 noon and concluded at 12:45 p.m.

Key Details of the Approved Debenture Issue

Enhanced Security Structure

The NCDs will be secured to the extent of 1.1x security cover, backed by multiple assets:

Primary Security Assets

Revised Terms and Strategic Implications

The updated terms reflect a more structured approach compared to the initial proposal. The shift from bullet repayment to quarterly amortizing payments over 36 months provides better cash flow management for both the company and investors. The enhanced security structure, including multiple property charges and guarantees, strengthens investor protection.

Regulatory Compliance

The approval follows proper regulatory disclosure requirements under SEBI LODR Regulations, with the company providing comprehensive details as per SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The company has committed to perfecting security charges within specified timelines and obtaining necessary NOCs from existing lenders.

Market Impact and Investor Perspective

This NCD issue represents a strategic capital-raising initiative that avoids equity dilution while providing attractive returns to debt investors. The 10% coupon rate, combined with quarterly interest payments and robust security cover, makes these debentures an appealing investment option in the current market environment. The pharmaceutical sector's stable cash flows further enhance the attractiveness of this debt instrument for institutional and eligible investors.